The safety and efficacy of viral vector-based gene therapies, vaccines, and other drug products can often be directly correlated with sample purity as well as the size, shape, and overall morphology of the particles that compose the active ingredient and excipients. To avoid product variability and contamination, drug manufacturers should periodically monitor their compounds’ primary particles and purity profiles throughout the development and manufacturing processes.